Marker Therapeutics, Inc. — Director's Dealing 2016

Nov 30, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2016-11-28

Reporting Person: Silverman Joshua (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-11-28	Employee Stock Option (Right to Buy)	$4.82	A	12500	Acquired	2026-11-27	Common Stock (12500)	Direct

Footnotes

F1: Represents options granted in connection with appointment as a director of the Company on November 28, 2016 under the Company's 2014 Omnibus Stock Ownership Plan. These shares shall vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, November 28, 2016.